Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype

Abstract

The results show that the pharmacokinetics of lornoxicam are dependent on CYP2C9 polymorphism. In particular, the presence of the CYP2C9*3 allele impairs the oral clearance of lornoxicam.